CANSINOBIO (06185): Frozen dried type B influenza and Bacillus binding vaccine has initiated phase I clinical trials and completed the enrollment of the first subject.

CANSINOBIO (06185) announced that the company's investigational freeze-dried b-type influenza Haemophilus influenzae conjugate vaccine has officially started Phase I clinical trials recently, and the first subject has been enrolled. Haemophilus influenzae is a gram-negative rod bacteria, and it is one of the main pathogens causing acute lower respiratory tract infection in children. It is classified into encapsulated and non-encapsulated types, both of which can cause infections. Non-encapsulated strains often cause diseases such as otitis media and sinusitis. Infections are mainly spread by bacteria colonized in the nasopharynx and adjacent areas; invasive infections secondary to bloodstream invasion are usually caused by encapsulated strains. Encapsulated strains are classified based on the chemical composition of the polysaccharide capsule, and so far, six serotypes have been discovered, with type b being responsible for approximately 95% of invasive Haemophilus influenzae diseases. The company's Hib vaccine is composed of purified Hib polysaccharide covalently bound to tetanus toxin protein and formulated in freeze-dried form. It is expected to induce humoral immunity against Hib after vaccination, providing protection to the vaccinated individuals. The company is developing a combination vaccine based on the acellular pertussis component, in which the in-development Hib vaccine is one of the components. As the Hib vaccine has not yet been approved for marketing, it needs to accumulate a certain amount of clinical data to support future registration application for the combination vaccine based on the acellular pertussis component.